We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+55.36%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$750M
AUM Growth
+$187M
Cap. Flow
+$114M
Cap. Flow %
15.17%
Top 10 Hldgs %
73.32%
Holding
52
New
16
Increased
12
Reduced
5
Closed
13

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$28.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22M
4
ASND icon
Ascendis Pharma A/S
ASND
+$17.9M
5
KURA icon
Kura Oncology
KURA
+$16.3M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$29.5M
2
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$25.9M
3
EDIT icon
Editas Medicine
EDIT
+$12M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.52M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.33%
2 Miscellaneous 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
26
Zai Lab
ZLAB
$2.93B
$4.31M 0.57%
+159,535
New +$4.45M
KIN
27
DELISTED
Kindred Biosciences, Inc.
KIN
$4.28M 0.57%
544,880
– –
SGMO
28
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.34M 0.44%
222,388
-2,345,731
-91% -$25.9M
CMTA
29
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.28M 0.44%
+194,166
New +$3.17M
ADVM
30
DELISTED
Adverum Biotechnologies
ADVM
$2.79M 0.37%
76,295
-11,150
-13% -$309K
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
$2.12M 0.28%
25,765
+15,765
+158% +$1.25M
XNCR icon
32
Xencor
XNCR
$1.94B
$2.06M 0.28%
+90,114
New +$2M
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
$1.63M 0.22%
30,000
+15,000
+100% +$768K
ACRS icon
34
Aclaris Therapeutics
ACRS
$885M
$1.55M 0.21%
60,000
-125,472
-68% -$3.36M
SYRS
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.53M 0.2%
+10,400
New +$1.96M
BMY icon
36
Bristol-Myers Squibb
BMY
$136B
$1.09M 0.14%
17,060
– –
ONC
37
BeOne Medicines Ltd
ONC
$41.5B
$1.01M 0.13%
+9,800
New +$730K
DCPH
38
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$855K 0.11%
+45,000
New +$824K
FSTX
39
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$269K 0.04%
+4,000
New +$229K
AGIO icon
40
Agios Pharmaceuticals
AGIO
$1.99B
– –
-23,300
Closed -$1.2M
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$31.7B
– –
-10,425
Closed -$831K
EDIT icon
42
CALL
Editas Medicine
EDIT
$485M
– –
-255,000
Closed -$4.32M
EDIT icon
43
Editas Medicine
EDIT
$485M
– –
-717,107
Closed -$12M
GILD icon
44
CALL
Gilead Sciences
GILD
$181B
– –
-500,000
Closed -$38M
NERV icon
45
Minerva Neurosciences
NERV
$231M
– –
-27,975
Closed -$1.98M
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-118,000
Closed -$1.1M
ALXN
47
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-569,500
Closed -$78.2M
NBRV
48
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-1,059
Closed -$2.77M
TTPH
49
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-31,670
Closed -$4.52M
ACHN
50
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-742,835
Closed -$3.41M
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2017 Portfolio in Review

As of Q3 2017, EcoR1 Capital held 52 positions worth $750M, up 33% from $563M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

EcoR1 Capital deployed $114M of net new capital in Q3 2017, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 2,860,019 shares worth $40M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $29.5M trimmed.

  • EcoR1 Capital's largest Q3 2017 buy was Immunomedics Inc: 2,860,019 shares worth $40M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q3 2017, an estimated $28M increase.
  • EcoR1 Capital's biggest Q3 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $29.5M.
  • EcoR1 Capital fully exited Editas Medicine in Q3 2017, selling an estimated $12M.
  • EcoR1 Capital's ten largest holdings make up 73% of its $750M portfolio in Q3 2017.
  • EcoR1 Capital opened 16 new positions and closed 13 in Q3 2017.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $750M.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.